Bio-Rad Laboratories Inc (BIO)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	3,048,330	3,146,770	3,138,870	3,277,250	3,157,980	3,140,160	3,249,700	3,303,420	1,990,480	2,466,290	2,289,090	2,175,320	2,139,840	2,323,860	2,132,580	2,082,590	2,180,160	2,047,630	2,087,940	2,031,640
Total current liabilities	US$ in thousands	522,799	558,176	581,982	589,623	568,708	570,677	613,714	648,331	680,938	649,916	587,052	609,892	631,536	986,657	926,895	869,254	905,495	434,040	445,977	444,306
Current ratio		5.83	5.64	5.39	5.56	5.55	5.50	5.30	5.10	2.92	3.79	3.90	3.57	3.39	2.36	2.30	2.40	2.41	4.72	4.68	4.57

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $3,048,330K ÷ $522,799K
= 5.83

The current ratio of Bio-Rad Laboratories Inc. has been consistently strong over the past eight quarters, ranging from 5.10 to 5.83. This indicates that the company has more than enough current assets to cover its current liabilities, reflecting a healthy liquidity position.

The upward trend in the current ratio from Q1 2022 to Q4 2023 suggests an improvement in the company's ability to meet its short-term obligations with its current assets. This may be attributed to effective management of working capital, such as maintaining optimal levels of inventory and accounts receivable, as well as efficient cash flow management.

Overall, the current ratio analysis indicates that Bio-Rad Laboratories Inc. has a strong financial position and is well-equipped to meet its short-term financial commitments, which could enhance its ability to pursue growth opportunities or navigate any unforeseen challenges in the future.